We are live on ! Find out more
ACRV icon

Acrivon Therapeutics
ACRV

48 hedge funds and large institutions have $32.7M invested in Acrivon Therapeutics in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 19 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more capital invested

Capital invested by funds: $21.2M → $32.7M (+$11.5M)

1.07% less ownership

Funds ownership: 56.78% → 55.71% (-1.1%)

9% less funds holding

Funds holding: 53 → 48 (-5)

42% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 19

45% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 11

Holders
48
Holders Change
-5
Holders Change %
-9.43%
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
11
Reduced
19
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$960K
2
Two Sigma Investments
Two Sigma Investments
New York
+$194K
3
Renaissance Technologies
Renaissance Technologies
New York
+$160K
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$146K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$129K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$498K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$455K
3
HF
HRT Financial
New York
-$173K
4
Goldman Sachs
Goldman Sachs
New York
-$169K
5
Millennium Management
Millennium Management
New York
-$156K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
26
Baker Bros. Advisors
New York
$41.3K – – –
Barclays
27
Barclays
United Kingdom
$36.1K -$1.35K -960 -5%
Goldman Sachs
28
Goldman Sachs
New York
$35.7K -$169K -120,313 -86%
Dimensional Fund Advisors
29
Dimensional Fund Advisors
Texas
$35.5K -$3.69K -2,625 -12%
Bank of America
30
Bank of America
North Carolina
$34.2K -$2.41K -1,713 -8%
Citigroup
31
Citigroup
New York
$29.5K -$22.6K -16,077 -50%
AWM
32
AAF Wealth Management
Massachusetts
$19.3K +$15K +10,678 New
TRCT
33
Tower Research Capital (TRC)
New York
$15.8K -$152 -108 -1%
Fidelity Investments
34
Fidelity Investments
Massachusetts
$15.6K -$1.73K -1,228 -12%
CUAMC
35
China Universal Asset Management Company
China
$9.98K -$1.1K -784 -12%
Federated Hermes
36
Federated Hermes
Pennsylvania
$4.39K +$152 +108 +5%
JP Morgan Chase
37
JP Morgan Chase
New York
$3.15K +$454 +323 +23%
Mirae Asset Global Investments
38
Mirae Asset Global Investments
South Korea
$2.2K +$7 +5 +0.4%
BNP Paribas Financial Markets
39
BNP Paribas Financial Markets
France
$2.15K +$277 +197 +20%
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$2K +$1.29K +917 +2,958%
GFM
41
GF Fund Management
China
$1.18K -$171 -122 -16%
Nisa Investment Advisors
42
Nisa Investment Advisors
Missouri
$1.06K – – –
RPA
43
Redwood Park Advisors
California
$905 – – –
Russell Investments Group
44
Russell Investments Group
United Kingdom
$871 – – –
FDCDDQ
45
Federation des caisses Desjardins du Quebec
Quebec, Canada
$724 – – –
EWA
46
EverSource Wealth Advisors
Alabama
$675 +$524 +373 New
SS
47
SBI Securities
Japan
$134 – – –
Jacobs Levy Equity Management
48
Jacobs Levy Equity Management
New Jersey
– -$455K -382,234 Closed
HF
49
HRT Financial
New York
– -$173K -145,895 Closed
Charles Schwab
50
Charles Schwab
California
– -$75.7K -63,636 Closed
1
2
3

ACRV Hedge Fund Activity: Q3 2025 in Review

48 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q3 2025, worth a combined $32.7M — up 54% from $21.2M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ACRV and 6 opened new positions — a net loss of 5 holders — while 19 trimmed existing stakes and 11 added.

The largest buyer was UBS Group, adding an estimated $960K. The largest seller was Citadel Advisors, cutting an estimated $498K.

  • 48 institutional investors held Acrivon Therapeutics (ACRV) as of Q3 2025, down from 53 in Q2 2025.
  • Funds reported $32.7M of Acrivon Therapeutics stock for Q3 2025, up 54% quarter-over-quarter.
  • 6 funds opened new Acrivon Therapeutics positions in Q3 2025 and 11 closed out, a net change of -5 holders.
  • The largest Acrivon Therapeutics buyer in Q3 2025 was UBS Group, an estimated $960K added.
  • The largest Acrivon Therapeutics seller in Q3 2025 was Citadel Advisors, an estimated $498K sold.

Based on aggregated 13F filings for Q3 2025.